However, the impact of renal disease induced CYP2C9 down-regulation on the clearance of the anti-hyperglycemic tolbutamide is not clear in human, because tolbutamide is almost exclusively eliminated by the kidneys, and is, therefore, contraindicated in patients with severe renal failure [49]. The gene discussed is CYP2C9; the disease is kidney failure.